|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 鼻气管鸟疫杆菌中国株的鉴定显示文摘通过形态特征检验、常规生长实验、API-20NE生化试剂盒检验、PCR检验和血清学检验从疑似副鸡嗜血杆菌的野外分离株中鉴定出2株鼻气管鸟疫杆菌。 | 陈小玲 宋程 罗廷荣 宋敏训 Terry T Bragg R Blackall P.J. | 2004 | 中国家禽2004，26，18： | 13 |
| 2 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 3 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 4 | Dysfunctional stem and progenitor cells impair fracture healing with age显示文摘Successful fracture healing requires the simultaneous regeneration of both the bone and vasculature;mesenchymal stem cells (MSCs) are directed to replace the bone tissue, while endothelial progenitor cells (EPCs) form the new vasculature that supplies blood to the fracture site. In the elderly, the healing process is slowed, partly due to decreased regenerative function of these stem and progenitor cells. MSCs from older individuals are impaired with regard to cell number, proliferative capacity, ability to migrate, and osteochondrogenic differentiation potential. The proliferation, migration and function of EPCs are also compromised with advanced age. Although the reasons for cellular dysfunction with age are complex and multidimensional, reduced expression of growth factors, accumulation of oxidative damage from reactive oxygen species, and altered signaling of the Sirtuin-1 pathway are contributing factors to aging at the cellular level of both MSCs and EPCs. Because of these geriatric-specific issues, effective treatment for fracture repair may require new therapeutic techniques to restore cellular function. Some suggested directions for potential treatments include cellular therapies, pharmacological agents, treatments targeting age-related molecular mechanisms, and physical therapeutics. Advanced age is the primary risk factor for a fracture, due to the low bone mass and inferior bone quality associated with aging;a better understanding of the dysfunctional behavior of the aging cell will provide a foundation for new treatments to decrease healing time and reduce the development of complications during the extended recovery from fracture healing in the elderly. | Diane R Wagner Sonali Karnik Zachary J Gunderson Jeffery J Nielsen Alanna Fennimore Hunter J Promer Jonathan W Lowery M Terry Loghmani Philip S Low Todd O McKinley Melissa A Kacena Matthias Clauss Jiliang Li | 2019 | World Journal of Stem Cells2019，11，6： | 3 |
| 5 | Immunoreactivity of CD45,a protein phosphotyrosine phosphatase,in Alzheimer' s disease 显示文摘 | Masliah E Mallory M Hansen L Alford M Albright T Terry R | 1991 | Acta Neuropathol( Berl )1991，83，1： | 2 |
| 6 | 膜型巨噬细胞集落刺激因子对人脑胶质细胞瘤的免疫治疗作用显示文摘摘要 目的 探讨基因转染膜型巨噬细胞集落刺激因子(mM-CSF)对U251MG人脑胶质瘤细胞的免疫治疗作用。方法 用逆转录病毒载体将mM-CSF基因转入U251MG细胞,采用流式细胞术检测mM-CSF的表达;通过细胞毒性实验、兔疫组化方法以及观察转染细胞在免疫缺陷小鼠体内的生长情况研究mM-CSF对U251MG细胞的作用。结果①获得了表达mM-CSF的MG-2F11细胞;②大鼠巨噬细胞、人外周血淋巴细胞(PBL)和人单核细胞均可杀伤MG-2F11细胞,但不能杀伤U251MG母细胞;③接种瘤细胞到裸小鼠皮下18 h后,侵入MG-2F11肿瘤的巨噬细胞明显多于侵入MG-VV(仅转染病毒载体的U251MG细胞)肿瘤的巨噬细胞;④接种MG-2F11细胞的8只裸小鼠均无肿瘤生长,而接种MG-VV细胞的8只裸小鼠中的7只有肿瘤生长(P<0.01);另一免疫缺陷更严重的NIH-bg-nu-xidBR 小鼠,接种MG-2F11细胞后8只中的1只有肿瘤生长,而接种MG-VV细胞后8只中的7只有肿瘤生长(P<0.01)。结论mM-CSF转染的人脑胶质瘤细胞致瘤性降低,有进一步对其进行临床研究的必要。 | 陈义军 Cheri Lloyd Ramon Sanchez Martin R Jadus H Terry Wepsic | 2002 | 中华神经外科疾病研究杂志2002，1，3： | 2 |
| 7 | Feedback links between economy-wide and farm-level policies : With application to irrigation water management in Morocco 显示文摘 | Terry R Ariel D Yacov T | 2005 | Journal of Policy Modeling2005，27，： | 1 |
| 8 | A two-stage technique for the digestion of forage crops显示文摘 | Tilley J M A Terry R A | 1963 | Br Grassl Soc1963，18，： | 1 |
| 9 | Marine fouling and its effects on off shore structures in the North Sea-a review 显示文摘 | Edyvean R G Terry L A Picken G B | 1985 | In- teraational Biodeterioration1985，21，4： | 1 |
| 10 | Study of the preparationconditions for NiMn204 grown from hydroxide precursors 显示文摘 | ASHCROFT Q TERRY I GOVER R | 2006 | J EurCeram Soc2006，26，6： | 1 |
| 11 | Comparative impulse voltage measurements at the national measurement laboratory (NML) CSIRO australia and the institute for national measurement standarda (INMS) NRC Canada 显示文摘 | Yi Li Juris Rungis Terry R | 2003 | IEEE Transactions on Instrument and Measurement2003，52，2： | 1 |
| 12 | Hydroxylamine oxidoreductase: a 20- heme, 200 000 molecular weight cytot:hromee with unusual denaturation properties which forms a 63 000 molecular weight monomer after heme removal显示文摘 | Terry K R Hooper A B | 1981 | Biocheudstry1981，20，24： | 1 |
| 13 | Immunohistochemical quantific-tion of the synapse-related protein synaptophysin in Alzheimer's disease显示文摘 | Masliah E Terry RD DeTeresa R | 1989 | Neurosci Lett1989，103，2： | 1 |
| 14 | Furfural hydrogenation over carbon-supported copper显示文摘 | Rao Rajeev S Baker R Terry K | 1999 | Catal Lett1999，60，12： | 1 |
| 15 | Effect of automatic tube current modulalion cm ratdiltion (lose and image qualily for low lube voltage muhidelector row CT angiography: phanlom study显示文摘 | Schindera S T Nelson R C Terry Y el al | 2009 | Acad Radiol2009，16，99： | 1 |
| 16 | Prenatal closure of the interatrial foramen显示文摘 | Wilson JG Lyon RA Terry R | 1953 | Am J Dis Child1953，85，3： | 1 |
| 17 | miR-21-mediated de- creased neutrophil apoptosis is a determinant of impaired coronary collateral growth in metabolic syndrome显示文摘 | Hutcheson R Terry R Hutcheson B | 2015 | Am J Physiol Heart Circ Physiol2015，308，11： | 1 |
| 18 | The patho genesis of calyceal diverticular calculi显示文摘 | Matlaga B R Miller N L Terry C | 2007 | Urol Res2007，35，1： | 1 |
| 19 | Importing the Semantic Web in UDDI显示文摘 | Takahiro Kawamura Terry R Payne | 2002 | IEEE transaction on Proceedings of Web Services2002，6，9： | 1 |
| 20 | X ray spectra estimation using attenuation measurements from 25 kVp to 18 MV显示文摘 | Waggener R G Blough M B Terry J A | 1999 | Med Phys1999，26，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员